The present application describes substituted piperidinyl modulators of
MIP-1.alpha. or CCR-1 or stereoisomers or pharmaceutically acceptable
salts thereof. In addition, methods of treating and preventing
inflammatory diseases such as asthma and allergic diseases, as well as
autoimmune pathologies such as rheumatoid arthritis and transplant
rejection using said modulators are disclosed.